<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02559154</url>
  </required_header>
  <id_info>
    <org_study_id>2010K059</org_study_id>
    <nct_id>NCT02559154</nct_id>
  </id_info>
  <brief_title>Modified Bortezomib-based Combination Therapy for Multiple Myeloma</brief_title>
  <official_title>An Open-Label Phase IV Study of the Efficacy of Bortezomib-based Combination Therapy the Treatment of Subjects With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <brief_summary>
    <textblock>
      To investigate the efficacy of a modified bortezomib based combination therapy for patients&#xD;
      with multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple myeloma (MM) is a common hematological malignancy in Chinese elderly population. The&#xD;
      application of novel drugs improved the clinical outcome and survival of MM patients,even&#xD;
      though MM remains an incurable hematological malignancy. Bortezomib is a typical one among&#xD;
      these novel agents, its application resulted in great success, but its adverse events and&#xD;
      high expense restricted its widely usage. Investigators modified the dose and frequency of&#xD;
      bortezomib administration in combination therapy: Patients in the modified group received&#xD;
      regimen with bortezomib (1.6mg/㎡) as an intravenous bolus once weekly on day 1, 8 in a 3&#xD;
      weeks cycle, in combination with dexamethasone,with or without doxorubicin/&#xD;
      cyclophosphamide/mitoxsnteone/thalidomide，while patients in the control group received&#xD;
      similar combination therapy except with conventional bortezomib (1.3mg/㎡) administration&#xD;
      twice weekly on day 1,4, 8,11.&#xD;
&#xD;
      The aim of this study is to investigate whether the modified bortezomib-based therapy may&#xD;
      attain a similar efficacy as the conventional ones.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease responses to treatment</measure>
    <time_frame>one year</time_frame>
    <description>Response evaluated by changes of serum M-component(g/L) through Serum quantitative immunoglobulins and Serum immunofixation electrophoresis.&#xD;
(g/L)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>modified BZ group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with newly diagnosed or pre-treated MM(prior therapy not including bortezomib) received regimen with bortezomib (1.6mg/㎡) as an intravenous bolus once weekly on day 1, 8 in a 3 weeks cycle, in combination with dexamethasone,with or without doxorubicin/ cyclophosphamide/mitoxsnteone/thalidomide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional BZ group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with newly diagnosed or pre-treated MM(prior therapy not including bortezomib) received bortezomib (1.3mg/㎡) administration twice weekly on day 1,4, 8,11 in a 3 weeks cycle, in combination with dexamethasone,with or without doxorubicin/ cyclophosphamide/mitoxsnteone/thalidomide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <arm_group_label>conventional BZ group</arm_group_label>
    <arm_group_label>modified BZ group</arm_group_label>
    <other_name>velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>conventional BZ group</arm_group_label>
    <arm_group_label>modified BZ group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <arm_group_label>conventional BZ group</arm_group_label>
    <arm_group_label>modified BZ group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>conventional BZ group</arm_group_label>
    <arm_group_label>modified BZ group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxsnteone</intervention_name>
    <arm_group_label>conventional BZ group</arm_group_label>
    <arm_group_label>modified BZ group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <arm_group_label>conventional BZ group</arm_group_label>
    <arm_group_label>modified BZ group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma based on standard diagnosis criteria:&#xD;
&#xD;
               -  plasmacytomas on tissue biopsy&#xD;
&#xD;
               -  bone marrow plasmacytosis&#xD;
&#xD;
               -  monoclonal immunoglobulin spike on serum electrophoresis&#xD;
&#xD;
               -  lytic bone lesions.&#xD;
&#xD;
          -  Must have relapsed or relapsed/refractory disease&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  All baseline studies must be performed within 21 days of enrollment.&#xD;
&#xD;
          -  ECOG performance status of 0 to 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal insufficiency (serum creatinine levels &gt; 2mg/dL)&#xD;
&#xD;
          -  Concomitant therapy medications that include corticosteroids&#xD;
&#xD;
          -  Peripheral neuropathy of Grade 3 or greater or painful Grade 2&#xD;
&#xD;
          -  Evidence of mucosal or internal bleeding and/or platelet refractory&#xD;
&#xD;
          -  ANC &lt; 1000 cells/mm3&#xD;
&#xD;
          -  Hemoglobin &lt; 8.0 g/dL&#xD;
&#xD;
          -  AST (SGOT and ALT) &gt; 2 x ULN&#xD;
&#xD;
          -  Intolerance to bortezomib or CC-5013 in the past or significant allergy to either&#xD;
             compound, boron or mannitol&#xD;
&#xD;
          -  Known hypersensitivity to thalidomide or the development of erythema nodosum&#xD;
&#xD;
          -  Active infection or serious co-morbid medical condition&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Prior malignancy with the last three years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, on in-situ&#xD;
             prostate cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guohua Liu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>September 21, 2015</study_first_submitted>
  <study_first_submitted_qc>September 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2015</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Daolin Wei</investigator_full_name>
    <investigator_title>Principal Investigator,Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

